Behind every research programme, natural history study and therapeutic development effort is a community of families, advocates, clinicians and supporters working to make progress possible. Over the past few months, the global MEF2C community has continued to build momentum on multiple fronts.
Inaugural MEF2C Awareness Day Brings Global Visibility
May 14, 2026 marked the first annual MEF2C Awareness Day, a date chosen to reflect the gene’s location on chromosome 5q14.3.
To mark the occasion, 60 landmarks across 36 US states and Canada were illuminated in blue, creating a powerful visual display of solidarity with individuals and families affected by MEF2C haploinsufficiency syndrome. Coordinated by the US MEF2C Foundation and supported by partner organisations around the world, the event demonstrated the growing international reach of the community.
Organisers intend for MEF2C Awareness Day to become an annual tradition, with preparations already underway for May 14, 2027.
Sources: [US MEF2C Foundation](https://www.usmef2cfoundation.org/events/mef2c-awareness-day), [Western Yukon coverage](https://www.wycokck.org/Engage-With-Us/News-articles/MEF2C-Awareness-Day-2026)
US Patient Registry Reaches New Milestone
The US MEF2C Foundation’s patient registry has now reached approximately 170 registered participants, representing one of the most important resources available to researchers preparing for future clinical studies.
According to foundation updates, the registry includes 168 consented participants, 150 approved laboratory reports, 100 completed medical histories and 40 donated blood samples. In January 2026, Boston Children’s Hospital hosted the second round of Landmark Patient Research Assessments, further strengthening the clinical dataset available to researchers.
Patient registries may not attract the same attention as new therapies, but they are a crucial part of the development process. Every additional participant helps researchers better understand the condition, identify meaningful clinical outcomes and prepare for future therapeutic trials.
Source: [US MEF2C Foundation](https://www.usmef2cfoundation.org/recentlydiagnosed)
Volare Study Delivers First Patient-Derived Stem Cell Lines
The Volare Study has reached another important milestone with the creation of the MEF2C community’s first patient-derived induced pluripotent stem cell (iPSC) lines. Developed through the study at Weill Cornell Medical Center, these stem cell lines are created from cells donated by people with MEF2C haploinsufficiency syndrome and can be transformed into different cell types for laboratory research. Researchers around the world will be able to use them to study the condition and test potential treatments directly in human cells carrying MEF2C mutations. The lines represent a diverse cross-section of the community and are expected to accelerate therapeutic development by providing a shared research resource available to MEF2C scientists globally.
Source: [Rare Bird Foundation](https://www.rare-bird.org/blog/volare-study-delivers-first-patient-derived-ipsc-lines)
MEF2C Family Foundation Hosts Pure Ima(gene)ation Benefit
In Saskatoon Saskatchewan, the MEF2C Family Foundation hosted its Pure Ima(gene)ation Benefit, bringing together families, researchers, sponsors and community supporters to raise funds for targeted MEF2C research initiatives.
The event highlighted the increasingly international nature of MEF2C advocacy. Alongside established organisations in the United States and United Kingdom, active foundations and family groups in Canada, Australia, Germany and elsewhere continue to contribute funding, awareness and research participation that benefit the entire community.
Source: [mef2c.org](https://mef2c.org/skbenefit)
Wings of Change Campaign Highlights Global Collaboration
The MEF2C Foundation UK’s ongoing Wings of Change: Stronger Together campaign continues to emphasise the collaborative effort required to move potential treatments from the laboratory into the clinic.
Working alongside the Rare Bird Foundation and other partners, the campaign highlights the progress being made across multiple therapeutic approaches. At present, two major treatment programmes are advancing in parallel: a gene therapy programme at UT Southwestern and an RNA-based therapeutic programme at the Medical University of South Carolina (MUSC). Both initiatives have received significant support from the MEF2C foundation community and represent important components of the broader therapeutic pipeline.
Source: [MEF2C Foundation UK Facebook](https://www.facebook.com/mef2cfoundation/posts/-wings-of-change-stronger-togetherthe-mef2c-foundation-is-proud-to-stand-alo/739926169134083/)
Taken together, these developments tell a story that extends beyond any single research paper or clinical programme. The foundations for future treatments are steadily being put in place. Funding is being raised, patient registries are expanding, natural history studies are collecting critical data, and awareness continues to grow around the world.
Scientific progress rarely happens overnight. Yet with every family that joins a registry, every donor who contributes, every researcher who shares data and every organisation that raises awareness, the MEF2C community moves another step closer to turning promising science into meaningful treatments.